NCR−ILC3s promote hepatocellular carcinoma (HCC) development in response to IL-23 to produce IL-17, which directly limits CD8+ T-cell immunity by enhancing lymphocyte apoptosis and inhibiting their proliferation (129). Here, CD8A is linked to hepatocellular carcinoma.